General Information of Drug (ID: DMH9JFZ)

Drug Name
NBI-5788 Drug Info
Synonyms Tiplimotide; CGP-77116; MSP-771; MSP-771A; APL (multiple sclerosis), Neurocrine/Novartis; Altered peptide ligand (MS), Neurocrine/Novartis
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 2 [1]
Cross-matching ID
PubChem CID
25084501
TTD Drug ID
DMH9JFZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Myelin basic protein (MBP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BHT-3009 DM7ZM1H Multiple sclerosis 8A40 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myelin basic protein (MBP) TT2RY5P MBP_HUMAN Binder [2]

References

1 ClinicalTrials.gov (NCT00001781) Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS). U.S. National Institutes of Health.
2 NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.
3 BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70.